KOSELUGO caps 25 mg bte 60 pce

7680674100027 CH-67410 L01EE04 07.16.1.

Reimbursement limitations:

KOSELUGO.01

Koselugo est indiqué dans le traitement des neurofibromatoses de type 1 (NF1) et des neurofibromes …

KOSELUGO caps 25 mg bte 60 pce
KOSELUGO caps 25 mg bte 60 pce
1 / 2
google

Details

Product number
6741002
CPT
-
Packaging group
60
Unit
Kapsel(n)
Composition
selumetinibum 25 mg ut selumetinibi hydrogenosulfas, tocofersolanum, Kapselhülle: hypromellosum, carrageenanum, kalii chloridum, E 171, E 132, E 172 (flavum), aqua purificata, cera carnauba, maydis amylum, Drucktinte: E 172 (rubrum), E 172 (flavum), E 132, cera carnauba, lacca, glyceroli mono-oleas, pro capsula.

Articles (1)

Koselugo 25 mg, Hartkapseln
Kapseln
60
View

Official Swissmedic V2 data

Additional information from the official database

Official medical documents

Patient information leaflet
Allemand
21/05/2025
Patient information leaflet
Français
21/05/2025
Patient information leaflet
Italien
21/05/2025
Professional SmPC
Allemand
21/05/2025
Professional SmPC
Français
21/05/2025
Professional SmPC
Italien
21/05/2025

Detailed composition

Substance Quantity Type Category
(N/A)
25.0 MG Substance Wirkstoff (Principe actif)
(N/A)
- Substance WIZUS
(N/A)
- Substance HNIDK
(N/A)
- Substance HNIDK
(N/A)
- Substance HNIDK
(N/A)
- Substance HNIDK
(N/A)
- Substance FNIDK
(N/A)
- Substance FIMDK
(N/A)
- Substance FTODK
(N/A)
- Substance HNIDK
(N/A)
- Substance HNIDK
(N/A)
- Substance HNIDK
(N/A)
- Substance FTODK
(N/A)
- Substance FTODK
(N/A)
- Substance FIMDK
(N/A)
- Substance HNIDK
(N/A)
- Substance HNIDK
(N/A)
- Substance HNIDK

Reimbursement information

Public price
CHF 12403.40
Specialties list
Yes
Generic
No

Reimbursement limitation

SL addition date: 01/06/2023

Authorization holder

Alexion Pharma GmbH

6340 Baar

Authorization information

Swissmedic authorization number
67410
Drug name
Koselugo, Hartkapseln
Galenic form
KAHA
ATC Code
L01EE04
Authorization status
Z
Dispensation category
A
First authorization
29/07/2022
Authorization expiration date
10/03/2030
IT number
07.16.1.
Domain
Human medicine
Field of application
Neurofibromatose Typ 1 (NF+) und plexiforme Neurofibrome (PN)

Packaging details

Description (FR)
KOSELUGO caps 25 mg bte 60 pce
Description (DE)
KOSELUGO Kaps 25 mg Ds 60 Stk
Market launch
29/07/2022
Narcotic (BTM)
No

Other packaging sizes

KOSELUGO caps 10 mg bte 60 pce
60 KAP
View